Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences
Manager
Telephone: 412-623-4701 or 412-586-9773
Patients and medical professionals may call 1-800-533-UPMC (8762) for more information.
University of Pittsburgh Schools of the Health Sciences

UPCI Vaccine Trial Offers Options for Patients With Slow-Growing Brain Tumors

PITTSBURGH, March 25, 2010 – A new vaccine trial available at the University of Pittsburgh Cancer Institute (UPCI) and Wake Forest University offers a treatment option for patients with low-grade gliomas, a slow-growing but lethal form of brain cancer. The phase one trial will evaluate the safety and immune response of a vaccine that targets the proteins typically made by glioma cells in combination with Poly-ICLC, an immune system stimulant.

The study is the first vaccine clinical trial specifically intended for the early stages of brain cancer development, according to principal investigator Hideho Okada, M.D., Ph.D., co-leader of UPCI’s Brain Tumor Program. Low-grade gliomas become deadly by eventually transforming into aggressive and rapidly growing tumors. By targeting tumors earlier in development, Dr. Okada and his team hope to induce protective immunity to prevent the growth of tumor cells. Current therapy for this disease is to manage the symptoms and remove or reduce the tumor.

The vaccine is completely synthetic and targets four of the most common antigens found in these brain tumors.

“We target multiple antigens because if you vaccinate against only one, tumor cells that do not produce that antigen can easily escape the immune attack and grow,” Dr. Okada explained. “Each cancer cell can have a different face than the other cancer cells next to it.”

To stimulate an immune response, he and his team created peptides, which are short chains of amino acids that resemble the antigens and combined them with a helper peptide as well as the potent immune enhancer poly-ICLC. Poly-ICLC is a synthetic molecule that mimics the molecular signature of viruses. It does not grow in patients’ bodies, but sends strong signals to activate an immune response against the glioma proteins.

“Patients with low-grade gliomas have a better quality of life for a longer period of time than those with high-grade gliomas,” said Dr. Okada. “They have healthier immune systems because they don’t require radiation therapy or chemotherapy, giving us plenty of time to measure their immune responses.”

Patients who are eligible and enroll in the trial will receive eight vaccinations and will be followed for up to two years. Patients with a favorable response may be eligible for a booster vaccination. For more information or for a patient referral, contact Dr. Okada at okada@upmc.edu.

This study is sponsored by the National Cancer Institute.

About UPCI

As the only NCI-designated comprehensive cancer center in western Pennsylvania, UPCI is a recognized leader in providing innovative cancer prevention, detection, diagnosis, and treatment; bio-medical research; compassionate patient care and support; and community-based outreach services. UPCI investigators are world-renowned for their work in clinical and basic cancer research.

©  UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences
Supplemental content provided by A.D.A.M. Health Solutions. All rights reserved.

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

For UPMC Mercy Patients: As a Catholic hospital, UPMC Mercy abides by the Ethical and Religious Directives for Catholic Health Care Services, as determined by the United States Conference of Catholic Bishops. As such, UPMC Mercy neither endorses nor provides medical practices and/or procedures that contradict the moral teachings of the Roman Catholic Church.

© UPMC
Pittsburgh, PA, USA UPMC.com